Precigen Inc Stock
Precigen Inc Stock price
Key metrics
| Market capitalization | $235.95m |
| Enterprise Value | $213.07m |
| P/E (TTM) P/E ratio | negative |
| EV/Sales (TTM) EV/Sales | 53.81 |
| P/S ratio (TTM) P/S ratio | 59.58 |
| P/B ratio (TTM) P/B ratio | 4.80 |
| Revenue growth (TTM) Revenue growth | -41.38% |
| Revenue (TTM) Revenue | $3.96m |
| EBIT (operating result TTM) EBIT | $-95.36m |
Is Precigen Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
Precigen Inc Stock Analysis
Analyst Opinions
4 Analysts have issued a Precigen Inc forecast:
Analyst Opinions
4 Analysts have issued a Precigen Inc forecast:
Financial data from Precigen Inc
| Sep '24 |
+/-
%
|
||
| Revenue | 3.96 3.96 |
41%
41%
|
|
| Gross Profit | 1.09 1.09 |
137%
137%
|
|
| EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -95 -95 |
9%
9%
|
| Net Profit | -140 -140 |
64%
64%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Precigen Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Precigen Inc Stock News
Company Profile
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The firm focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. It operates through the following segments: PGEN Therapeutics, ActoBio, MBP Titan, Trans Ova and All Other. The PGEN Therapeutics segment is advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders and infectious diseases. The ActoBio segment involves in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The MBP Titan segment comprises of Methane Bioconversion Platform, and associated technologies, personnel, and facilities The Trans Ova segment includes provides advanced reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
| Head office | United States |
| CEO | Helen Sabzevari |
| Employees | 202 |
| Founded | 1998 |
| Website | www.precigen.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
